miRisten / Thalia Therapeutics, City of Hope - LARVOL DELTA

miRisten….is currently in a Phase 1 dose-escalation clinical trial at City of Hope in the United States, evaluating patients with relapsed or refractory AML (Investing.com) - "Thalia expects to report top-line data from the trial in the first half of 2027....The company stated the Phase 1 trial continues to enroll patients."

P1 data • Trial status • Acute Myelogenous Leukemia

Thalia Therapeutics receives China patent for AML drug miRisten (Investing.com) - "The patent covers the use of miRisten in China and adds to existing patents granted in the U.S., UK, Germany, France, Japan, and European Patent Organisation countries. The intellectual property was originally licensed from City of Hope to Sanmirna Therapeutics Inc., which Thalia acquired in July 2026."

Patent • Acute Myelogenous Leukemia

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: City of Hope Medical Center | Suspended ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=20 | Suspended | Sponsor: City of Hope Medical Center | N=12 ➔ 20

Enrollment change • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=20 | Suspended | Sponsor: City of Hope Medical Center | Recruiting ➔ Suspended

Trial suspension • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology